| Literature DB >> 33755619 |
Abstract
Ansuvimab-zykl (Ebanga), a human monoclonal antibody, has been approved to treat Zaire ebolavirus (Ebolavirus) infection.The most common adverse effects of the drug are fever, tachycardia, diarrhea, vomiting, hypotension, tachypnea, and chills; these are also common symptoms of Ebolavirus infection.Entities:
Mesh：
Substances：
Year: 2021 PMID： 33755619 DOI： 10.1097/01.NAJ.0000742484.81331.b2
Source DB: PubMed Journal: Am J Nurs ISSN： 0002-936X Impact factor: 2.220